Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship between p53 and p27 expression following HER2 signaling.
Casalini P, Iorio MV, Berno V, Bergamaschi A, Børresen Dale AL, Gasparini P, Orlandi R, Casati B, Tagliabue E, Ménard S. Casalini P, et al. Among authors: gasparini p. Breast. 2007 Dec;16(6):597-605. doi: 10.1016/j.breast.2007.05.007. Epub 2007 Jun 28. Breast. 2007. PMID: 17604627 Free article.
Radiation effects on development of HER2-positive breast carcinomas.
Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, Camerini T, Sozzi G, Fossati-Bellani F, Ménard S, Tagliabue E. Castiglioni F, et al. Among authors: gasparini p. Clin Cancer Res. 2007 Jan 1;13(1):46-51. doi: 10.1158/1078-0432.CCR-06-1490. Clin Cancer Res. 2007. PMID: 17200337
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: gasparini p. Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27. Cancer Res. 2014. PMID: 25164009
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.
Turdo F, Bianchi F, Gasparini P, Sandri M, Sasso M, De Cecco L, Forte L, Casalini P, Aiello P, Sfondrini L, Agresti R, Carcangiu ML, Plantamura I, Sozzi G, Tagliabue E, Campiglio M. Turdo F, et al. Among authors: gasparini p. Oncotarget. 2016 Oct 25;7(43):69649-69665. doi: 10.18632/oncotarget.11935. Oncotarget. 2016. PMID: 27626701 Free PMC article.
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: gasparini p. Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19. Oncogene. 2017. PMID: 27641338 Free PMC article.
The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
Forte L, Turdo F, Ghirelli C, Aiello P, Casalini P, Iorio MV, D'Ippolito E, Gasparini P, Agresti R, Belmonte B, Sozzi G, Sfondrini L, Tagliabue E, Campiglio M, Bianchi F. Forte L, et al. Among authors: gasparini p. BMC Cancer. 2018 May 23;18(1):586. doi: 10.1186/s12885-018-4500-9. BMC Cancer. 2018. PMID: 29792166 Free PMC article.
605 results